ReviewClinical pharmacokinetics2024

Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.

Yan Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.